Antiviral drug strategies /
Antiviral drug strategies /
edited by Erik De Clercq.
- 1 online resource (xx, 406 pages) : illustrations (some color).
- Methods and principles in medicinal chemistry ; v. 50 .
- Methods and principles in medicinal chemistry ; v. 50. .
Includes bibliographical references and index.
Outlook of the antiviral drug era, now more than 50 years after description of the first antiviral drug / Inhibition of HIV entry / Targeting integration beyond strand transfer: development of second-generation HIV integrase inhibitors / From saquinavir to darunavir: the impact of 10 years of medicinal chemistry on a lethal disease / Acyclic and cyclic nucleoside phosphonates / Helicase-primase inhibitors: a new approach to combat herpes simplex virus and varicella zoster virus / Cyclophilin inhibitors / Alkoxyalkyl ester prodrugs of antiviral nucleoside phosphates and phosphonates / Maribavir: a novel benzimidazole ribonucleoside for the prevention and treatment of cytomegalovirus diseases / Anti-HCMV compounds / Lethal mutagenesis as an unconventional approach to combat HIV / Recent progress in the development of HCV protease inhibitors / Antiviral RNAi: how to silence viruses / Neuraminidase inhibitors as anti-influenza agents / From TIBO to rilpivirine: the chronicle of the discovery of the ideal nonnucleoside reverse transcriptase inhibitor / Erik De Clercq -- José A. Esté -- Arnout R.D. Voet, Marc De Maeyer, Frauke Christ, Zeger Debyser -- Marie-Pierre de Béthune, Anik Peeters, Piet Wigerinck -- Richard L. Mackman, Tomas Cihlar -- Subhajit Biswas, Hugh J. Field -- Grégoire Vuagniaux, Arnaud Hamel, Rafael Crabbé, Hervé C. Porchet, Jean-Maurice Dumont -- James R. Beadle, Karl Y. Hostetler -- Karen K. Biron -- Graciela Andrei, Robert Snoeck -- Pinar Iyidogan, Karen S. Anderson -- Nagraj Mani, Bhisetti G. Rao, Tara L. Kieffer, Ann D. Kwong -- Karin J. von Eije, Ben Berkhout -- Willard Lew, Michael Z. Wang, Xiaowu Chen, James F. Rooney, Choung Kim -- Erik De Clercq.
By focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses. It begins with a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases, neuraminidases, RNA polymerases, helicases and primases, as well as their known inhibitors. The final section contains several cases studies of recent successful antiviral drug development. Edited by Erik de.
9783527635955 3527635955 9783527635979 3527635971 1283140918 9781283140911
9786613140913
10.1002/9783527635955 Wiley InterScience http://www3.interscience.wiley.com
Antiviral agents--Development.
Antiviral agents--Development.
MEDICAL--Pharmacology.
Antiviral Agents.
Drug Discovery.
Electronic books.
RS431.A66 / A68 2011
615.7924
QV268.5
Includes bibliographical references and index.
Outlook of the antiviral drug era, now more than 50 years after description of the first antiviral drug / Inhibition of HIV entry / Targeting integration beyond strand transfer: development of second-generation HIV integrase inhibitors / From saquinavir to darunavir: the impact of 10 years of medicinal chemistry on a lethal disease / Acyclic and cyclic nucleoside phosphonates / Helicase-primase inhibitors: a new approach to combat herpes simplex virus and varicella zoster virus / Cyclophilin inhibitors / Alkoxyalkyl ester prodrugs of antiviral nucleoside phosphates and phosphonates / Maribavir: a novel benzimidazole ribonucleoside for the prevention and treatment of cytomegalovirus diseases / Anti-HCMV compounds / Lethal mutagenesis as an unconventional approach to combat HIV / Recent progress in the development of HCV protease inhibitors / Antiviral RNAi: how to silence viruses / Neuraminidase inhibitors as anti-influenza agents / From TIBO to rilpivirine: the chronicle of the discovery of the ideal nonnucleoside reverse transcriptase inhibitor / Erik De Clercq -- José A. Esté -- Arnout R.D. Voet, Marc De Maeyer, Frauke Christ, Zeger Debyser -- Marie-Pierre de Béthune, Anik Peeters, Piet Wigerinck -- Richard L. Mackman, Tomas Cihlar -- Subhajit Biswas, Hugh J. Field -- Grégoire Vuagniaux, Arnaud Hamel, Rafael Crabbé, Hervé C. Porchet, Jean-Maurice Dumont -- James R. Beadle, Karl Y. Hostetler -- Karen K. Biron -- Graciela Andrei, Robert Snoeck -- Pinar Iyidogan, Karen S. Anderson -- Nagraj Mani, Bhisetti G. Rao, Tara L. Kieffer, Ann D. Kwong -- Karin J. von Eije, Ben Berkhout -- Willard Lew, Michael Z. Wang, Xiaowu Chen, James F. Rooney, Choung Kim -- Erik De Clercq.
By focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses. It begins with a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases, neuraminidases, RNA polymerases, helicases and primases, as well as their known inhibitors. The final section contains several cases studies of recent successful antiviral drug development. Edited by Erik de.
9783527635955 3527635955 9783527635979 3527635971 1283140918 9781283140911
9786613140913
10.1002/9783527635955 Wiley InterScience http://www3.interscience.wiley.com
Antiviral agents--Development.
Antiviral agents--Development.
MEDICAL--Pharmacology.
Antiviral Agents.
Drug Discovery.
Electronic books.
RS431.A66 / A68 2011
615.7924
QV268.5